ABAnnemie Buelens

Annemie Buelens

*This is an algorithmically generated author record based on publicly available information.

Annemie Buelens has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Viral Dynamic Model‐Informed Dose Selection of Mosnodenvir Prophylaxis against DENV ‐3 in a Controlled Human Infection Model

    by Nele Goeyvaerts, Xavier Woot de Trixhe, Martine Neyens, Thomas N. Kakuda, Liesbeth Van Wesenbeeck, Annemie Buelens, Freya Rasschaert, Anna Durbin, Oliver Ackaert

    Dengue virus (DENV) infection is a significant global health threat. Mosnodenvir (JNJ‐64281802) is a pan‐serotype small molecule antiviral blocking DENV replication. A Phase IIa study (NCT05048875) evaluated the antiviral activity, safety, and pharmacokinetics of mosnodenvir as prophylaxis against DENV‐3 in a controlled human infection model (CHIM). A combined population pharmacokinetic (PopPK) and viral dynamic model (VDM) was developed to estimate the prophylactic effect of mosnodenvir and to inform dose selection. The PopPK model is a two‐compartment model based on plasma pharmacokinetic data from three Phase I studies and Cohort 1 of the Phase IIa study. Mosnodenvir exposure metrics were estimated for participants receiving high, medium, or low doses. A VDM with an immune response compartment adequately described DENV‐3 RNA profiles for placebo participants and was subsequently extended by including a sigmoid E max relationship with average mosnodenvir concentration at steady state ( C avg,ss ) to capture the antiviral effect on virion production rate. Simulations supported daily and weekly mosnodenvir dosing regimens to further characterize the pharmacokinetic/pharmacodynamic relationship in Cohort 2. Based on the complete Phase IIa study data, the basic reproductive number for DENV‐3 in this CHIM was estimated at 21.7, and the typical C avg,ss required to achieve complete virus eradication was estimated to be 1,410 ng/mL. In conclusion, the combined PopPK and VDM approach effectively informed dose selection and characterized the pharmacokinetic‐antiviral activity relationship, supporting the development of mosnodenvir as a prophylactic treatment for dengue infection.

  • Open Access

    A Prospective Cohort Study of Primary Dengue Virus Infection in Medellín, Colombia

    by Andrea Trujillo, Liesbeth Van Wesenbeeck, Lina Salazar, Liliana López, Lotke Tambuyzer, Annemie Buelens, Kim De Clerck, Oliver Lenz, Leen Vijgen, Marnix Van Loock, et al.

    Background: The evaluation of antiviral or vaccination strategies for the prevention of dengue infections in a traveler population would require extensive and complex studies. This prospective study aimed to identify a cohort of dengue naïve participants living in Medellín, a dengue endemic area, as a proxy for travelers and to determine the incidence of primary dengue virus (DENV) infection (symptomatic and asymptomatic) in this cohort. In Colombia, epidemic dengue waves occur every 3–4 years, with infected Aedes mosquitoes present in ~80% of the territory, including Medellín. Methods: Participants > 16 years of age, living in Medellín, were screened for anti-DENV immunoglobulin G (IgG). DENV seronegative participants were enrolled in this study. A serological anti-DENV survey was performed, with semiannual sample collections for up to 2 years. Acute DENV infections were evaluated by monitoring fever and testing for DENV nonstructural protein 1 and/or RNA. Results: Of the 4885 screened participants, 3008 participants (62%) were DENV seronegative and enrolled. Among them, 2263 (75%) completed this study, and 2644 (88%) had at least one serosurvey visit after baseline. Of those, 52 (2%) had laboratory-confirmed DENV seroconversion, and 19 (<1%) had febrile illness, but none had laboratory-confirmed DENV infection. Conclusions: This study identified a cohort of predominantly students, seronegative at study start, living in Medellín and serving as a proxy for a prospective DENV infection traveler population. Laboratory-confirmed primary DENV infection was found in 2% of participants, with <1% reporting febrile illnesses, meeting the WHO criteria for probable clinical dengue cases.


  • Open Access

    Dengue Infections Among Household Contacts of Symptomatic Index Cases: Implications for Community-Based Intervention Studies

    by Erik Koehne, Liesbeth Van Wesenbeeck, Martin L. Hibberd, Annemie Buelens, Michiko Toizumi, Kim De Clerck, Leen Vijgen, Ole Lagatie, Lucy Masdin, Hien Anh Thi Nguyen, et al.

    Background: Dengue is a global health concern, with half of the world’s population at risk and no antiviral treatment available. This Phase 0 study investigated dengue infections among household contacts (HHCs) of dengue index cases (ICs) and assessed the feasibility of conducting a Phase 2 trial for a novel antiviral. Methods: Participants were enrolled in Nha Trang, Vietnam, from April 2022 to February 2023. Dengue ICs were identified within 72 h of fever onset, and their healthy adult HHCs enrolled within 48 h. Blood samples and questionnaires were collected bi-weekly for four weeks, with a follow-up visit on day 40. DENV RT-qPCR, NS1, and anti-DENV IgM/IgG ELISAs were performed. Results: Overall, 130 dengue ICs and 301 HHCs were enrolled, with 91.7% (276/301) completing all follow-up visits. Baseline anti-DENV IgG showed prior dengue infections in 262/301 HHCs (87.0%). Fifty HHCs were excluded from the HHC infection analysis based on evidence of a DENV infection (viral load [VL], NS1, IgM, and IgG results) at enrollment. During follow-up, 2.0% of HHCs (5/251) had DENV infections based on virological parameters (DENV RNA and/or NS1 positivity), and anti-DENV IgG/IgM seroconversion was detected in 7.2% (18/251). Conclusions: This study demonstrated the operational feasibility of a dengue IC-HHC design for a Phase 2 trial.

  • Open Access

    The IL-6 hypothesis in COVID-19: A phase 2, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of free IL-6 sequestration by the monoclonal antibody sirukumab in severe and critical COVID-19

    by Robert L. Gottlieb, Meredith Clement, Paul Cook, Audra Deveikis, Kap Sum Foong, Philip Robinson, Jihad Slim, Cedric W. Spak, Annemie Buelens, Katleen Callewaert, et al.


  • Open Access

    Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region

    by Christoph Sarrazin, Erkki Lathouwers, Monika Peeters, Bjorn Daems, Annemie Buelens, James Witek, Yves Wyckmans, Bart Fevery, Thierry Verbinnen, Anne Ghys, et al.